Effect of Azithromycin in People with CF and B. Cepacia
Funding for this trial has been provided in full or in part by Cystic Fibrosis Foundation Therapeutics, Inc.
Number of Participants Being Recruited:
Single / Multi-Center:
STUDY BACKGROUND INFORMATION:
This study will examine the effectiveness of azithromycin in improving the lung function of CF patients infected with bacteria from the Burkholderia cepacia complex. In patients with CF, pulmonary infections with bacteria from the Burkholderia cepacia complex are often associated with a more rapid decline in lung function. Because of the resistance of these types of bacteria to many antibiotics, treatment options are often limited. Previous trials have shown that CF patients infected with other types of bacteria can benefit from the prolonged administration of azithromycin. Scientists now want to test the effectiveness of this approved antibiotic in combating bacteria of the Burkholderia cepacia complex when compared to a placebo. A total of 45 individuals 19 or older are expected to enroll in this study.
>= 19 Years
>= 30 Percent Predicted
P. aeruginosa status:
B. cepacia status:
Other Primary Eligibility Requirements:
Note: Detailed eligibility criteria information may be available on clinicaltrials.gov. If a specific
trial listing for this trial is available, a link to the specific clinicaltrials.gov listing will be present in the "More Information" section below.
FOR MORE INFORMATION:
Sponsor Contact Information:
Tullis, Elizabeth (416) 864-5406 email@example.com